Tecaginlimab clinical trials
Also written GEN1042.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses tecaginlimab has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GEN1042
- 3
Studies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tecaginlimab.
- Aug 2027A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid TumorsPhase 1 · Genmab
Studies
Open first, then newest update. How each study uses tecaginlimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid TumorsActive, not recruitingPhase 1GenmabNCT06057038Written as GEN1042Report a problem
- A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid TumorsTerminatedPhase 1/2GenmabNCT05491317Written as GEN1042Report a problem
- GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsActive, not recruitingPhase 1/2GenmabNCT04083599Written as GEN1042Report a problem
Tested with established drugs · 3 — they are given beside it
- A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid TumorsActive, not recruitingPhase 1GenmabNCT06057038Written as GEN1042Report a problem
- A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid TumorsTerminatedPhase 1/2GenmabNCT05491317Written as GEN1042Report a problem
- GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsActive, not recruitingPhase 1/2GenmabNCT04083599Written as GEN1042Report a problem
Codes
What other systems call tecaginlimab · ClinicalTrials.gg INT014433
- UNII (FDA) 27X2015N23TECAGINLIMABOne source FDA
- NCI Thesaurus C168604TecaginlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 27X2015N23 | TECAGINLIMAB | One source FDA |
| NCI Thesaurus | C168604 | Tecaginlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.